ARTICLE | Clinical News
Toviaz fesoterodine: Phase IV data
January 28, 2013 8:00 AM UTC
A double-blind, international Phase IV trial in 1,955 patients with OAB showed that once-daily 8 mg Toviaz met the primary endpoint of reducing the mean number of urge urinary incontinence episodes pe...